• Inform and educate congressional offices on the importance of Pennsylvania's life sciences community to patients and the Commonwealth's economy.
• Share our concerns and support with PA congressional offices on implementation of Medicare Part D and B provisions in the Inflation Reduction Act (e.g. negotiations in Part D, inflationary rebate penalty, out-of-pocket cap for seniors, and vaccine cost sharing). Urge legislators to support legislation that aligns breakthrough device designation at FDA with a coverage pathway at CMS - HR 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
• Support reintroduction of the VALID Act (previously HR 4128). Support the PASTEUR Act to incentivize the development of novel antimicrobial medicines. (S1355 and HR2490) Support PAHPA Reauthorization and stress the importance of investing in public health and pandemic preparedness.
• Support funding increases for the National Institutes of Health, National Science Foundation, and Food and Drug Administration
• Support repeal of R&D Amortization (S866 and HR 2673) to reduce tax liability for small/growing life sciences companies. HR 2673 and S866 titled "American Innovation and R&D Competitiveness Act of 2023. Support the Orphan Drug Tax Credit and oppose proposals to further alter it, or the Orphan Drug Act.
• Keep legislators apprised of developments/news in the Commonwealth's life sciences ecosystem.
• Support policies that strengthen IP/Patent protections - e.g. Stronger Patents Act and express concern for policies, like the TRIPS Waiver, that waive patent protections for COVID diagnostics and therapeutics, and share concerns on proposals, such as march-in rights, that undermine IP protections and innovation. Share concerns with Pennsylvania delegation specifically on Department of Commerce and HHS proposed framework for agencies on the exercise of march-in rights.
• Support policies, like the HELP Copays (HR 830) Act, that increase access to medicines.

Duration: January 1, 2020 to present

General Issues: Health Issues, Medicare/Medicaid, Medical/Disease Research/Clinical Labs, Budget/Appropriations, Taxation/Internal Revenue Code, Science/Technology, Copyright/Patent/Trademark, Insurance, Small Business, Economics/Economic Development, Pharmacy

Spending: about $29,696 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2020: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Commerce - Dept of (DOC)